TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38497241
Drug: BI 690517
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 690517 (all doses)
Study: 38497241
Drug: BI 690517
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 690517 10 mg
Study: 38498030
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT)-based smoking cessation smartphone app, 4 weeks intervention
Study: 38498084
Drug: Obinutuzumab (G)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (G) in combination with CHOP (G-CHOP)
Study: 38498139
Drug: Risankizumab 150
Normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 150 mg (subcutaneous)
Study: 38498142
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg CM-chitosan (KioMedine)
Study: 38498141
Drug: Placebo (inactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactive drug) followed by Risankizumab 150 mg
Study: 38498835
Drug: PPOS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPOS with oral micronized progesterone (200 mg from stimulation Day 1)
Study: 38499015
Drug: Subcutaneous ND0612
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ND0612 (levodopa-carbidopa 60.0/7.5 mg/mL)
Study: 38499015
Drug: Oral levodopa-carbidopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levodopa-carbidopa
Study: 38499015
Drug: Subcutaneous ND0612
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ND0612
Study: 38499238
Drug: NTM-PD progression
Normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTM-PD progression (defined as initiation of treatment or clinician's intention to treat)
Study: 38499323
Drug: Bolus volume
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus volume of 10-20 mL/kg
Study: 38499323
Drug: Exclusive administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exclusive administration of balanced crystalloids at 1 hour
Study: 38499323
Drug: Exclusive administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exclusive administration of balanced crystalloids at 24 hours
Study: 38499943
Drug: EOI block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOI block with 40 ml 0.25% bupivacaine after anesthesia induction
Study: 38500190
Drug: Pharmacist-facilitated medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-facilitated medication reviews with feedback on medication issues and recommendations to physicians.
Study: 39282907
Drug: Ponsegromab 100
Normalized name: Ponsegromab
DrugBank: Ponsegromab (DB18943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponsegromab 100 mg
Study: 39282907
Drug: Ponsegromab 200
Normalized name: Ponsegromab
DrugBank: Ponsegromab (DB18943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponsegromab 200 mg
Study: 39282907
Drug: Ponsegromab 400
Normalized name: Ponsegromab
DrugBank: Ponsegromab (DB18943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponsegromab 400 mg
Study: 38500476
Drug: Zandelisib 60
Normalized name: Zandelisib
DrugBank: Zandelisib (DB18245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zandelisib 60 mg on Days 1-7 plus zanubrutinib 80 mg twice daily continuously in 28-day cycle
Study: 38500841
Drug: 14-day bismuth
Normalized name: bismuth subcitrate 14 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day bismuth quadruple therapy
Study: 38501082
Drug: Cultural Formulation
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultural Formulation Interview (CFI) administered in the intervention group
Study: 38501087
Drug: Adapted Internet-Delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted Internet-Delivered Cognitive Behaviour Therapy (ICBT) program
Study: 38501087
Drug: Non-adapted Internet-Delivered
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adapted Internet-Delivered Cognitive Behaviour Therapy (ICBT) program
Study: 38501219
Drug: Mivavotinib 80
Normalized name: Mivavotinib
DrugBank: Mivavotinib (DB16849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivavotinib 80 mg once-daily plus nivolumab 3 mg/kg on days 1 and 15 in 28-day cycles
Study: 38501219
Drug: Mivavotinib 80
Normalized name: Mivavotinib
DrugBank: Mivavotinib (DB16849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivavotinib 80 mg plus nivolumab 3 mg/kg
Study: 38501262
Drug: Niraparib maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib maintenance treatment
Study: 38501946
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue photodynamic therapy (MB-PDT) performed after percutaneous abscess drainage with laser illumination at a fluence rate of 20 mW/cm.
Study: 38501946
Drug: Standard-of-care abscess
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care abscess management including image-guided percutaneous drainage and antibiotics.
Study: 38501980
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline and placebo capsules (Control)
Study: 38502056
Drug: Bisoprolol (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (dose not specified)
Study: 38502074
Drug: Aspirin, 81
Normalized name: Aspirin, 81 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 81 mg once daily for 6 months
Study: 38502074
Drug: Placebo, identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, identical pills once daily for 6 months
Study: 38502193
Drug: Rapamycin dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin dosing schedule
Study: 38502195
Drug: FF-10101 (oral),
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF-10101 (oral), doses ranging from 10 to 225 mg per day and 50 to 100 mg twice daily (BID)
Study: 38502195
Drug: FF-10101 (oral),
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF-10101 (oral), recommended phase 2 dose was 75 mg BID
Study: 38502425
Drug: Lacosamide 50
Normalized name: lacosamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide 50 mg Bid for three months
Study: 38502819
Drug: Combination Lavender/Peppermint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Lavender/Peppermint Aromatherapy Patch
Study: 38503417
Drug: WT1/DC-vaccine immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: WT1/DC-vaccine immunotherapy combined with conventional antiglioma treatment (chemoradiation with oral temozolomide 90 mg/m2)
Study: 38503415
Drug: Weekly injections
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly injections of semaglutide for 30 weeks
Study: 38503755
Drug: Exemestane plus
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane plus everolimus and palbociclib (100 mg palbociclib, 5 mg everolimus, 25 mg exemestane)
Study: 38504173
Drug: Recombinant zoster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant zoster vaccine (RZV), administered in two doses two months apart.
Study: 38505928
Drug: FA-acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: FA-acetaminophen 1000 mg
Study: 38505928
Drug: ES-acetaminophen 1000
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ES-acetaminophen 1000 mg
Study: 38505928
Drug: LG-ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LG-ibuprofen 400 mg
Study: 38506710
Drug: NOUS-PEV (vector-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOUS-PEV (vector-based personalized vaccine)
Study: 38506889
Drug: MOABP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOABP with an oral regimen of neomycin and metronidazole (n=277)
Study: 38506900
Drug: Cytotoxic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic treatments (chemo- and radiotherapy)
Study: 38506900
Drug: Fertility preservation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fertility preservation treatments (freezing of gametes and gonadal tissue)
Study: 38507476
Drug: CNS-active potentially
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS-active potentially inappropriate medication (PIM)
Study: 38507476
Drug: Potential subadequate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential subadequate antidepressant dosing
Study: 38507752
Drug: scAAV9/JeT-GAN (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: scAAV9/JeT-GAN (a self-complementary adeno-associated virus-based gene therapy)
Study: 38508135
Drug: KN046 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: KN046 plus chemotherapy (pemetrexed for non-sq-NSCLC and paclitaxel plus carboplatin for sq-NSCLC)
Study: 38508835
Drug: Givinostat (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Givinostat (oral, flexible dose based on weight, twice a day for 72 weeks)
Study: 38508835
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo, twice a day for 72 weeks)
Study: 38508844
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (Enalapril or Valsartan)
Study: 38508877
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (other antihypertensive drugs)
Study: 38508975
Drug: Topical diacerein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diacerein
Study: 38509517
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of finerenone with an ACEi or ARB
Study: 38509662
Drug: Smartphone-based speech
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based speech therapy app for 1 hour per day, 5 days per week, for 4 weeks, with guideline-based standard stroke care.
Study: 38509699
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of RV5 and IPV
Study: 38509699
Drug: Staggered administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Staggered administration of RV5 and IPV
Study: 38510299
Drug: End of
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End of anthracycline therapy
Study: 38510299
Drug: CTRCD during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTRCD during adjuvant therapy
Study: 38510502
Drug: High HDL-C
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High HDL-C (>70 mg/dL)
Study: 38510502
Drug: Low HDL-C
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low HDL-C (<50 mg/dL)
Study: 38510502
Drug: Average HDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average HDL-C (50-70 mg/dL)
Study: 38510979
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsules containing polyunsaturated fatty acids (PUFAs) taken once daily for 12 months
Study: 38510979
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsules containing olive oil (placebo)
Study: 38510983
Drug: Vebicorvir (VBR)
Normalized name: Vebicorvir
DrugBank: Vebicorvir (DB18784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vebicorvir (VBR) + Nucleos(t)ide Reverse Transcriptase Inhibitors (NrtIs)
Study: 38511087
Drug: Subcutaneous Ig20Gly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Ig20Gly (50-200 mg/kg) administered weekly for 24 weeks (Epoch 2)
Study: 38511087
Drug: Subcutaneous Ig20Gly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Ig20Gly (100-400 mg/kg) administered every 2 weeks for 12 weeks (Epoch 3)
Study: 38511087
Drug: Treatment-emergent adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent adverse events during Epochs 2 and 3
Study: 38511563
Drug: Mobocertinib at
Normalized name: Mobocertinib
DrugBank: Mobocertinib (DB16390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mobocertinib at 160 mg once daily
Study: 38512387
Drug: Basal Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal Insulin Switch
Study: 38512694
Drug: Vutrisiran (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vutrisiran (25 mg subcutaneous injection once every 3 months)
Study: 38512694
Drug: Patisiran (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran (0.3 mg/kg intravenous infusion once every 3 weeks)
Study: 38512960
Drug: Delta variant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta variant infection (after 2 doses)
Study: 38512960
Drug: Omicron BA.4/5
Normalized name: COVID-19 vacc, bv (Orig, Omicron BA.4/5) (Pfizer)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omicron BA.4/5 infection (after 3 doses)
Study: 38513060
Drug: Inorganic nitrate
Normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inorganic nitrate (12 mmol potassium nitrate once daily for 5 days)
Study: 38513170
Drug: PD-1/PD-L1 inhibitor-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 inhibitor-based therapy
Study: 38513368
Drug: mRNA-1273 (100-µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (100-µg doses)
Study: 38513368
Drug: mRNA-1273 (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (after dose 2)
Study: 38513368
Drug: mRNA-1273 (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (after dose 3)
Study: 38513368
Drug: mRNA-1273 (post-additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (post-additional dose)
Study: 38513436
Drug: Alirocumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (150 mg biweekly)
Study: 38513684
Drug: Co-administered Na-GST-1
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administered Na-GST-1 on Alhydrogel plus Na-APR-1(M74) on Alhydrogel and glucopyranosyl lipid A in aqueous formulation (GLA-AF)
Study: 38513684
Drug: Co-administered ENGERIX-B
Normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administered ENGERIX-B hepatitis B vaccine (HBV) and saline placebo
Study: 38513689
Drug: mRNA-1273 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (50 µg) booster vaccination and QIV co-administered (Coad group)
Study: 38513689
Drug: mRNA-1273 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (50 µg) booster vaccination and QIV sequentially administered (Seq group)
Study: 38513746
Drug: Motion style
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motion style acupuncture treatment (MSAT) combined with integrative Korean medicine (IKM)
Study: 38513888
Drug: ω-3 FA
Normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 FA supplement (DHA 0.8 g and EPA 1.7 g daily)
Study: 38514081
Drug: Anti-PD-1 inhibitors
Normalized name: anti-inhibitor coagulant complex 1 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 inhibitors
Study: 38515146
Drug: Enhanced cross-sectoral
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enhanced cross-sectoral collaboration and treatment during the first 3 months following diagnosis.
Study: 38515149
Drug: Anlotinib-based therapy
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib-based therapy
Study: 38515275
Drug: DISC-0974 (7-56
Approvals — FDA: no, EMA: no, PMDA: no
Description: DISC-0974 (7-56 mg, administered IV or SC)
Study: 38515445
Drug: Cognito's Evoked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognito's Evoked Gamma Therapy System (CogTx-001), self-administered daily for one hour over 6 months.
Study: 38515445
Drug: Sham treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment, self-administered daily for one hour over 6 months.
Study: 38515445
Drug: Cognito's Evoked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognito's Evoked Gamma Therapy System (CogTx-001)
Study: 38515570
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg administered by intravenous infusion on day 1 every 3 weeks (Q3W)
Study: 38516099
Drug: Sintilimab 200
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200 mg on day one and oral daily anlotinib 12 mg on days 1-14 once every three weeks per cycle
Study: 38517235
Drug: Pralatrexate 25
Normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pralatrexate 25 mg/m²
Study: 38517242
Drug: HBP levels
Normalized name: chlorpheniramine maleate Oral Tablet [Teldrin HBP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBP levels higher than 35 ng/mL
Study: 38517907
Drug: albendazole-ivermectin treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: albendazole-ivermectin treatment
Study: 38517907
Drug: albendazole treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: albendazole treatment
Study: 38517907
Drug: hookworm treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hookworm treatment (both arms)
Study: 38518479
Drug: Online group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online group-based Acceptance and Commitment Therapy (ACT), 8 sessions as online group therapy.
Study: 38518549
Drug: Domatinostat 200
Normalized name: Domatinostat
DrugBank: Domatinostat (DB17521)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domatinostat 200 mg twice daily (BD) plus avelumab 10 mg/kg every 2 weeks (2qw)
Study: 38518549
Drug: Domatinostat 200
Normalized name: Domatinostat
DrugBank: Domatinostat (DB17521)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domatinostat 200 mg BD plus avelumab 10 mg/kg 2qw
Study: 38518789
Drug: mRNA-1273.214 primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273.214 primary series (25 μg)
Study: 38518789
Drug: mRNA-1273.214 booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273.214 booster dose (10 μg)
Study: 38518789
Drug: mRNA-1273.214 primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273.214 primary series and booster dose
Study: 38519053
Drug: GD2BATs (anti-CD3×anti-GD2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GD2BATs (anti-CD3×anti-GD2 bispecific antibody armed T cells)
Study: 38519055
Drug: Odronextamab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odronextamab monotherapy
Study: 38519416
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) 40,000 IU/mL weekly infusion
Study: 38519581
Drug: MAG-EPA (3g
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAG-EPA (3g daily for 7 weeks)
Study: 38519581
Drug: Placebo (3g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3g daily for 7 weeks)
Study: 38519913
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg every 3 weeks until progression or unmanageable toxicity, combined with SBRT (45 Gy in 3 fractions)
Study: 38519988
Drug: Tocilizumab added
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab added to standard of care (SOC) maintenance treatment, n = 25
Study: 38520501
Drug: Vortioxetine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (5-20 mg)
Study: 38520670
Drug: Pepinemab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pepinemab (20 mg/kg) administered intravenously on Days 1 and 15 of a 28-day cycle
Study: 38521132
Drug: Once-daily radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily radiation therapy (66 Gy/33 fractions/6.5 weeks)
Study: 38521132
Drug: Twice-daily radiation
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily radiation therapy (45 Gy/30 fractions/3 weeks)
Study: 38521191
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (65.7 mg ferrous fumarate)
Study: 38521524
Drug: Tailored anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored anticoagulant treatment based on individualised assessment of rVTE and major bleeding risks after 3 months of therapy.
Study: 38521524
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of anticoagulant treatment for patients with high rVTE and low bleeding risk.
Study: 38521524
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of anticoagulant treatment for patients with low rVTE risk after 3 months.
Study: 38521533
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone antagonist given once daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
Study: 38521883
Drug: High-dose tafamidis
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tafamidis (80/61 mg po qd)
Study: 38521893
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg iberdomide
Study: 38521931
Drug: Produce prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Produce prescription program (intervention)
Study: 38522503
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum antimüllerian hormone (AMH) concentration
Study: 38523000
Drug: PCSK9 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCSK9 inhibitors (PCSK9i); 28% of patients